APTATARGETS S.L

AptaTargets is a clinical-stage biotechnology company focused on developing therapeutic aptamers, particularly ApTOLL, aimed at treating acute inflammatory conditions such as stroke and myocardial infarction. Founded in 2015, AptaTargets S. L is based in Madrid, Spain, where it focuses on the development of its lead product, ApTOLL, an immune modulator targeting TLR4. The company's recent funding round, a Series B completed in October 2020, raised EUR 5 million from investors including the Centre for Technological & Industrial Development and Inveready Asset Management.

The company has completed a total of 5 deals to date. AptaTargets specializes in therapeutic aptamers, focusing on ApTOLL, which modulates the immune response by targeting TLR4 to reduce brain damage from acute ischemic stroke. ApTOLL also has potential applications for other acute conditions such as intracerebral hemorrhage and myocardial infarction. The company is advancing ApTOLL through clinical trials and aims to expand its therapeutic portfolio internationally.

In the most recent year, 2023, AptaTargets reported revenue of EUR 2,170,284. 80 with an EBITDA of EUR -5,720. 50, primarily generated through partnerships and potential agreements with pharmaceutical companies involved in the development and commercialization of ApTOLL. AptaTargets plans to utilize proceeds from its EUR 5 million Series B funding round to advance ApTOLL through clinical trials, with aspirations for market entry in the coming years.

The company is exploring expansion into European and global markets, targeting regions that require innovative treatments for acute inflammatory conditions, leveraging its clinical data to form strategic partnerships with healthcare institutions and pharmaceutical collaborators.